(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. David McDermott discussing results of a phase 2 study of belzutifan + cabozantinib for the treatment of advanced clear cell renal cell carcinoma (RCC). HIF transcription activates several genes associated with clear cell RCC, including VEGF. Cabozantinib, a VEGF, AXL, and MET inhibitor, is approved for advanced clear cell RCC, with VEGF blockade leading to tumor hypoxia and HIF activation. Belzutifan is a potent, selective small molecular inhibitor, thus targeting both the HIF-2alpha and the VEGF pathways may improve outcomes for patients with advanced clear cell RCC: